Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
62.86
+1.36 (2.21%)
At close: Sep 25, 2026, 4:00 PM EDT
62.90
+0.04 (0.06%)
After-hours: Sep 25, 2026, 7:53 PM EDT
BMY Market Cap
BMY has a market cap or net worth of $128.41 billion as of September 25, 2026. Its market cap has increased by 42.86% in one year.
Market Cap
128.41B
Enterprise Value
161.99B
1-Year Change
42.86%
Ranking
Category
Stock Price
$62.86
ChartMarket Cap Chart
Since December 1, 1998, BMY's market cap has increased from $124.14B to $128.41B, an increase of 3.44%. That is a compound annual growth rate of 0.12%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 25, 2026 | 128.41B | 16.94% |
| Dec 31, 2025 | 109.81B | -4.28% |
| Dec 31, 2024 | 114.71B | 9.88% |
| Dec 29, 2023 | 104.40B | -31.75% |
| Dec 30, 2022 | 152.98B | 10.54% |
| Dec 31, 2021 | 138.39B | -1.27% |
| Dec 31, 2020 | 140.17B | 34.03% |
| Dec 31, 2019 | 104.58B | 23.27% |
| Dec 31, 2018 | 84.84B | -15.41% |
| Dec 29, 2017 | 100.30B | 2.69% |
| Dec 30, 2016 | 97.67B | -14.90% |
| Dec 31, 2015 | 114.76B | 17.20% |
| Dec 31, 2014 | 97.92B | 11.89% |
| Dec 31, 2013 | 87.51B | 62.68% |
| Dec 31, 2012 | 53.80B | -9.91% |
| Dec 30, 2011 | 59.72B | 31.75% |
| Dec 31, 2010 | 45.33B | -9.38% |
| Dec 31, 2009 | 50.02B | 8.68% |
| Dec 31, 2008 | 46.03B | -12.28% |
| Dec 31, 2007 | 52.47B | 1.36% |
| Dec 29, 2006 | 51.76B | 15.13% |
| Dec 30, 2005 | 44.96B | -9.80% |
| Dec 31, 2004 | 49.85B | -10.13% |
| Dec 31, 2003 | 55.46B | 23.69% |
| Dec 31, 2002 | 44.84B | -54.56% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 648.67B |
| AbbVie | 468.43B |
| Merck & Co. | 365.34B |
| Novartis AG | 270.93B |
| Amgen | 219.55B |
| Gilead Sciences | 187.69B |
| Novo Nordisk | 170.00B |
| Pfizer | 160.62B |